BIOCRYST PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expensed and Capitalized, Amount
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Share-based Payment Arrangement, Expensed and Capitalized, Amount of $16.03 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Expensed and Capitalized, Amount
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 · last filed 2026-05-06
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2026-03-31 was $16.03M, a 25.00% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2025-12-31 was $23.82M, a 11.63% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2025-09-30 was $18.64M, a 8.09% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2025-03-31 was $21.37M.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2025 was $85.14M, a 30.15% increase from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2024 was $65.41M, a 17.62% increase from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2023 was $55.62M.
| Period end | Share-based Payment Arrangement, Expensed and Capitalized, Amount 3 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 6 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 9 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 12 month |
|---|---|---|---|---|
| 2026-03-31 | $16.03M 10-Q · filed 2026-05-06 | $39.85M derived: sum of 2 quarters · filed 2026-05-06 | $58.49M derived: sum of 3 quarters · filed 2026-05-06 | |
| 2025-12-31 | $23.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $42.47M derived: sum of 2 quarters · filed 2026-02-26 | $85.14M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $18.64M 10-Q · filed 2025-11-04 | $61.32M 10-Q · filed 2025-11-04 | ||
| 2025-03-31 | $21.37M 10-Q · filed 2026-05-06 | $42.71M derived: sum of 2 quarters · filed 2026-05-06 | $59.96M derived: sum of 3 quarters · filed 2026-05-06 | |
| 2024-12-31 | $21.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $38.59M derived: sum of 2 quarters · filed 2026-02-26 | $65.41M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $17.25M 10-Q · filed 2025-11-04 | $44.07M 10-Q · filed 2025-11-04 | ||
| 2023-12-31 | $55.62M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |